- Trial Phase
- Phase 3 (completed)
- Time to Market
- Unknown — Phase 3 is complete but no regulatory submission has been announced. If filed after the merger closes (late 2026/early 2027), potential approval could be 12-24 months post-filing.
- Why 4/10
- No hard drug-specific binary catalyst (PDUFA or pivotal readout) is scheduled for ITM-11 in the next ~12 months. The Phase 3 COMPETE trial is complete but no regulatory filing has been announced. The December 1, 2026 shareholder vote on the ITM merger is a corporate M&A catalyst, not a drug-specific regulatory catalyst per the rubric. ITM-11 is one of several assets in the ITM pipeline being acquired by a company with multiple other programs (Illuccix, Gozellix, Pixclara, Zircaix, etc.), so it is not a single-asset binary for Telix.
Monitor the Telix shareholder vote on December 1, 2026 for the ITM merger — approval is the key near-term catalyst for ITM-11's path forward. Post-merger, watch for regulatory submission plans for ITM-11 in GEP-NETs, which would compete with Novartis' Lutathera. The elevated short volume (~63% weighted ratio) suggests significant bearish positioning that could amplify a positive vote outcome.
Price Chart
Executive Summary
ITM-11 (177Lu-edotreotide) is a late-stage targeted radioligand therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that has completed Phase 3 development at ITM Isotope Technologies Munich SE. Telix Pharmaceuticals (TLX) announced a transformational merger with ITM on September 21, 2026 for $1.65B upfront plus up to $700M in milestones, bringing ITM-11 into Telix's pipeline alongside ITM's commercial-scale lutetium-177 production capabilities. The merger is subject to a Telix shareholder vote on December 1, 2026 and expected to close by end of FY 2026. ITM-11 would compete directly with Novartis' Lutathera, the current standard-of-care peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Telix trades at ~$9.15 with a ~$3.4B market cap and strong buy consensus (mean PT ~$20.52, ~124% implied upside), but faces elevated short volume (~63% weighted ratio).
How It Works
ITM-11 is a targeted radiation therapy for neuroendocrine tumors. It combines a synthetic molecule (edotreotide) that binds to somatostatin receptors — proteins found in high numbers on neuroendocrine tumor cells — with the radioactive isotope lutetium-177. When injected, the drug travels to tumor cells and delivers localized radiation, killing cancer cells while largely sparing healthy tissue. This is the same class of therapy as Novartis' approved drug Lutathera.
Trial Status
ITM-11 has completed the Phase 3 COMPETE trial evaluating 177Lu-edotreotide for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug is currently not yet filed for regulatory approval. It is being acquired by Telix Pharmaceuticals via the ITM merger, which is expected to close by end of FY 2026 subject to shareholder approval (vote December 1, 2026).
The Two-Sided Case
Upcoming Catalysts
- Telix shareholder vote on ITM merger — December 1, 2026
- Merger closing (expected by end of FY 2026, subject to approval)
- Potential regulatory submission plans for ITM-11 post-merger
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Telix Pharmaceuticals Ltd 6-K TLX ·Originating report